Applied DNA Sciences, Inc. (NASDAQ:APDN) Q1 2023 Earnings Call Transcript

Yi Chen: Okay. Got it. When will you feel comfortable to provide some topline guidance, could it happen later this fiscal year?

Beth Jantzen: It really will be a function of depending on when we get the PGx up and running and have more progress on the cGMP and the LRx front. But mostly in that time frame more soon thereafter.

James Hayward: And we will need contracts that give us the ability to forecast.

Yi Chen: Okay. So the package filing, is it going to occur in the current quarter or in the first half of this calendar year?

James Hayward: So we’ll be filing in the current quarter. Clay, are you comfortable with that?

Clay Shorrock: I am. Our clinical validation E, wound up in December. We’ve pulled the data facts together. It looks good. We’re just in the process of finalizing the package check file.

Yi Chen: Got it. Okay. Great. Thank you.

James Hayward: You’re welcome.

Operator: Showing no further questions, this concludes our question-and-answer session. I would like to turn the conference back over to Dr. Hayward for any closing remarks.

James Hayward: Yes, we’d like to thank you all for participating in today’s dialogue, and we look forward to speaking with you again at the end of the current quarter. Thank you.

Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.